



**FABRICIO J. ALARCON, MD**  
Department of General Internal Medicine,  
Cleveland Clinic.

**J. HARRY ISAACSON, MD**  
Department of General Internal Medicine,  
Cleveland Clinic.

**KATHLEEN FRANCO-BRONSON, MD**  
Director of psychiatry residency training,  
head of consultation and liaison psychiatry,  
Department of Psychiatry and Psychology,  
Cleveland Clinic.

# Diagnosing and treating depression in primary care patients: Looking beyond physical complaints

## ABSTRACT

Depression is common, but often overlooked because patients with depression often present with somatic complaints rather than psychological ones. Primary care physicians must learn to recognize depression and be thoroughly familiar with its treatment, because this disease is common and serious.

## KEY POINTS

Up to 20% of patients seen in a primary care office may meet the criteria of a mood disorder.

Depression in the primary care setting should not be a diagnosis of exclusion. When diagnosing depressive disorders, physicians should pay particular attention to the character and duration of symptoms.

Depression may be secondary to alcohol or drug abuse, and remits rapidly when the offending substance is eliminated.

All antidepressant drugs are approximately equally effective, but certain considerations—age, previous response to a particular drug, side effect profile, concurrent nonmood psychiatric disorders, interactions, need for serum level monitoring, risk of overdose, and cost—make the selection process more rational than arbitrary.

**A**LTHOUGH NEW DRUGS have revolutionized the treatment of depression, this disorder remains a major challenge to the primary care physician. Depression is one of the most common conditions in the primary care office. Yet the signs and symptoms are not straightforward, are often masked by complaints of physical problems, and often coexist with other medical problems.

In this guide for the primary care physician, we outline some tips for identifying depression in different age groups, present our approach to initiating treatment, and provide some advice for following patients after treatment has begun.

## DEPRESSION IS COMMON

The prevalence of mental illness in patients who present to primary care physicians is remarkably high. Up to 70% have psychological or psychiatric complaints,<sup>1</sup> with mood disorders among the most common.<sup>2</sup> Community samples find that from 2% to 9% of patients meet the full criteria for diagnosis of a mood disorder according to the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition (DSM-IV),<sup>3</sup> and approximately 13% have a “subthreshold” diagnosis; although they have fewer symptoms, these patients have considerable impairment of quality of life and would benefit from monitoring and treatment.<sup>4,5</sup>

The prevalence of major depression in the general population ranges from 4% to 9%. Depression affects as many as 10% of men and 20% of women at some point in their lives,<sup>6</sup> and an estimated 2.5% of men and 8% of women at any given time.



TABLE 1

### Diagnostic criteria for major depressive disorder and dysthymic disorder

#### Major depressive disorder

Five of the following symptoms must be present for at least 2 weeks, nearly every day. At least one of the first two criteria must be present:

- Depressed mood
- Loss of interest or pleasure
- Loss of appetite or weight
- Insomnia or hypersomnia
- Psychomotor retardation or agitation
- Fatigue or loss of energy
- Feelings of worthlessness or guilt
- Diminished ability to think or concentrate
- Recurrent thoughts of death or suicide

#### Dysthymic disorders

Chronic depressed mood more often than not, lasting for at least 2 years. The symptoms are not as severe or disabling as a major depressive disorder and include two or more of the following features:

- Poor appetite or overeating
- Insomnia or hypersomnia
- Low energy or fatigue
- Low self-esteem
- Poor concentration or difficulty making decisions
- Feelings of hopelessness

SOURCE: DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS, 4TH EDITION

#### DEPRESSION IS SERIOUS

In the 15 months after the depression is diagnosed, mortality rates in affected patients are four times higher than in age-matched controls.<sup>6</sup>

Depression is also costly, second only to cardiovascular disease in the time lost from work and lost productivity that it causes.<sup>7</sup> By one estimate,<sup>8</sup> depression costs society \$44 billion per year, of which 72% consists of indirect costs—loss of productivity and absenteeism

(55%) and loss of earnings due to suicide (17%). The direct costs of treatment account for only 28.4%, and antidepressant medication costs account only for 2%. These findings strongly support the economic benefit of detecting and treating depression.

#### DEPRESSION IS OFTEN OVERLOOKED

Primary care physicians recognize mood disorders in only 25% to 50% of affected patients and miss the diagnosis of major depressive disorder in up to 66%.<sup>9</sup> One reason is that patients typically present with physical symptoms such as fatigue, headache, and insomnia rather than a depressed mood.<sup>10</sup> One study<sup>11</sup> found an organic cause of these symptoms in only 16% of outpatient cases, with treatment often ineffective. Therefore, it is important to consider depression early in the course of new unexplained somatic complaints.

#### NOT A DIAGNOSIS BY EXCLUSION

Depression in the primary care setting should not be a diagnosis of exclusion. Several clues, such as frequent primary care visits for unexplained symptoms, one or more pain complaints, or a recent stressful life event, should prompt an early, more thorough search for the presence of the formal diagnostic criteria for mood disorders (TABLE 1).<sup>1,3</sup> When diagnosing depressive disorders, physicians should pay particular attention to the character and duration of symptoms. A dysphoric or depressed mood lasting more than 2 weeks and accompanied by neurovegetative and psychological symptoms is a tip-off (TABLE 1), especially when social and occupational functioning is diminished.

In screening for depression, primary care physicians can use a questionnaire such as the General Health Questionnaire (GHQ),<sup>12</sup> the Zung Self-Rating Depression Scale (ZSRDS),<sup>13</sup> the Center for Epidemiological Studies-Depression Scale,<sup>14</sup> or the Beck Depression Inventory,<sup>15</sup> or use a rating scale such as the Primary Care Evaluation of Mental Disorders.<sup>2</sup>

If the patient meets DSM-IV criteria for a depressive disorder, the primary care physician should rule out alcohol or drug abuse. Depression may be secondary to these prob-

Consider depression early in the course of new unexplained somatic complaints



TABLE 2

**Atypical presentations of depression in older adults**

Accidental overdose  
 Alcohol or substance abuse  
 Anorexia, weight loss  
 Anxiety disorders  
 Incontinence  
 Loneliness, social withdrawal  
 Marital discord  
 Obsessions and compulsions  
 Other behavioral disturbances  
 Paranoid states  
 Physical disorders and pain  
 Pseudodementia  
 Screaming  
 Unlawful behaviors (shoplifting, inappropriate sexual acts)

lems and remits rapidly when the offending substance is eliminated.

**Diagnosing depression in older patients**

Although the risk factors for depression are the same in older patients as in younger ones, the symptoms may differ. Young adults more often present with subjective dysphoria (a sad, "blue" feeling or loss of interest or pleasure), whereas older patients are more likely to have:

- Vegetative symptoms (eg, sleep and appetite disturbances, somatic complaints).
- Cognitive dysfunction (eg, concentration difficulty, apathy).
- Signs of social withdrawal, isolation, and increased dependency.
- Atypical presentations (TABLE 2).<sup>16</sup>

The somatic symptoms of depression in the elderly are frequently attributed incorrectly to other medical problems or to aging.<sup>17</sup>

**Depression with coexisting medical illness**

Depression is common in the medically ill,<sup>18</sup> but the diagnosis is not always straightforward. Fewer than half of depressed patients with coexisting medical illness are diagnosed, and of these, only 30% receive appropriate treatment.<sup>19</sup>

Often, families and caregivers believe that depressive symptoms are to be expected in patients with medical illness. Further, the symptoms of depression and of medical conditions often overlap. However, it is a mistake to assume that all depressive symptoms are due to the medical illness and therefore do not need treatment. As part of the medical evaluation, it is important to investigate symptoms suggestive of depression (eg, fatigue, weight loss, impaired sexual function) and to treat empirically with antidepressant medication, particularly if the likelihood of underlying systemic illness is low.

Medications sometimes cause or exacerbate symptoms of depression; these include antihypertensives, anabolic steroids, histamine type-2 receptor blockers, anticonvulsants, levodopa, certain antibiotics, anti-inflammatory drugs, antiarrhythmic drugs, metoclopramide, baclofen, and benzodiazepines.

**Bereavement**

It is normal to have some symptoms of depression after the death of a loved one, although there is some ethnic variability. However, when intense symptoms persist after 2 months, it is advisable to reevaluate. The physician should especially consider antidepressant treatment when the patient has feelings of excessive guilt or worthlessness or thoughts that he or she would be better off dead. Withdrawing from family and friends is of great concern. Functional impairment and depression persisting 2 months often predict continued major depression at 13 and 25 months.<sup>20,21</sup>

**■ ACUTE-PHASE MANAGEMENT**

Whenever possible, the practitioner and patient should decide together what type of treatment to use: medication, psychotherapy, medication and psychotherapy combined, electroconvulsive therapy, or, for seasonal affective disorder, light therapy. Such shared decision-making is likely to increase adherence and effectiveness. TABLE 3 outlines factors that affect the choice of treatment in the acute phase.<sup>22</sup>

If the depressive episodes are milder, less chronic, nonrecurrent, and nonpsychotic, the physician may wish to extend the evaluation over two or three visits and monitor the symp-

**Do not assume that all depressive symptoms are due to the medical illness**





toms, to determine if the patient may improve with psychotherapy alone, without needing further intervention.

The most effective type of treatment is a combination of psychotherapy and medication. Psychiatrists are more likely than primary care physicians to provide this treatment.<sup>23</sup> Primary care providers often emphasize pharmacologic treatment and are reported to prescribe drugs for patients with psychiatric diagnoses 50% more often than psychiatrists.<sup>24</sup> This is perhaps more true for benzodiazepines used for anxiety disorders. On the other hand, primary care doctors tend to prescribe antidepressants at a lower dosage than may be therapeutic.

The most effective types of psychotherapy for major depression have been cognitive behavioral psychotherapy and interpersonal psychotherapy. Both of these are very specific manual-driven therapies and are not offered by all mental health professionals. Supportive counseling alone is certainly not considered adequate treatment for major depression but may be helpful in increasing the patient's adherence to the medication. It also gives the opportunity to discuss fears of taking "drugs" (antidepressants) and side effects that might require alteration of the prescription. This supportive counseling in conjunction with the medication can clearly be offered by the primary care physician.

If suicidal thoughts are mentioned, they require exploration. It is best to make a psychiatric referral whenever there is concern about the patient's safety.

### Reasons to use a particular drug

No single antidepressant is clearly more effective than another; the reported rates of initial response are as high as 60% to 70% for all available agents vs about 20% for placebo.<sup>25</sup> Empirical trials are the only way to select the best drug for a particular patient, but several factors make the process more rational.

**Age.** The elderly tend to better tolerate antidepressants with fewer anticholinergic effects, such as selective serotonin reuptake inhibitors (SSRIs), bupropion, and secondary-amine tricyclics.

**A previous response to a particular drug,** in the patient or a first-degree family member, is an indication to try the same drug again.

**TABLE 3**

### Indications for different treatments for depression

#### Medication alone

- Chronic depression
- Failure to respond to psychotherapy
- Family history of depression
- Melancholic cases
- More severe depression
- Patient preference
- Prior positive response
- Psychosis
- Recurrent episodes

#### Psychotherapy alone

- Availability
- Contraindication to medication
- Less chronic cases
- Less severe cases
- Nonpsychotic cases
- Patient preference
- Prior positive response

#### Combination therapy

- Availability
- Chronic cases
- More severe cases
- Partial response to either therapy alone
- Patient preference
- Personality disorder

#### Electroconvulsive therapy

- Contraindication to medication
- Failure of other therapies
- Need for rapid response
- Prior positive response
- Psychotic cases
- Very severe cases

**All anti-depressants produce response rates of 60% to 70%**

**Side-effect profile.** An extensive review of side effects of antidepressant medications is beyond the purpose of this article, and has been done by Muzina and Malone<sup>26</sup> in the November/December 1996 issue of this journal. The most common side effects are outlined in **TABLE 4.**<sup>22,27</sup> Tricyclic antidepressants, although less expensive, tend to cause more side effects than SSRIs and the other newer antidepressants. Among the tricyclics the tertiary amines such as amitriptyline, doxepin, and imipramine tend to produce more side effects (especially anticholinergic) than the secondary amines such as desipramine and nortriptyline.



TABLE 4

**Common side effects of antidepressant medications\***

DRUG	ANTICHOLINERGIC EFFECTS	DROWSINESS	INSOMNIA	ORTHOSTATIC HYPOTENSION	ARRHYTHMIA	GI EFFECTS	WEIGHT GAIN
<b>Tricyclics</b>							
<b>Tertiary amines</b> (amitriptyline, doxepin, imipramine)	3–4	3–4	0–1	2–4	2–3	0–1	3–4
<b>Secondary amines</b> (desipramine, nortriptyline, protriptyline)	1–2	1	0–1	2	2	0	0–1
<b>Other tricyclic antidepressants</b>							
Amoxapine	2	2	2	2	3	0	1
Bupropion	0	0	2	0	1	1	0
Maprotiline	2	3	0	0	1	0	2
Mirtazapine	3	4	0	1	0–1	1	0
Trazodone	0	4	0	1	1	1	0
Venlafaxine	1	0–1	2	0–1	0	4	0
<b>Selective serotonin reuptake inhibitors</b>							
Fluoxetine	0	0–1	2–3	0	0	3	0
Fluvoxamine	1	0–1	2	0	0	4	0
Paroxetine	2	1–2	2	0	0	3	0
Sertraline	0	0–1	2	0	0	3	0
<b>Monoamine oxidase inhibitors</b>							
	1	1	2	2	0	1	2

\*0 = none, 1 = mild, 2 = moderate, 3 = moderate to severe, 4 = severe

SOURCE: DATA FROM US DEPARTMENT OF HEALTH AND HUMAN SERVICES, REFERENCE 20, AND VEITH ET AL, REFERENCE 26

**SSRIs can increase the levels of many drugs, including warfarin**

Patients with heart disease should receive drugs such as SSRIs or bupropion, which are not associated with hypotension or cardiac conduction changes.<sup>28,29</sup> Patients with a history of seizures should not receive antidepressants that lower the threshold for seizures, such as clomipramine, maprotiline, amoxapine, and bupropion.<sup>30</sup>

**Concurrent nonmood psychiatric disorders** can sometimes be treated with a single agent for both conditions. Clomipramine and fluoxetine, for example, have been found effective in both depression and obsessive-compulsive disorder.

**Interactions with drugs or food.** All available antidepressants can have significant drug interactions.

SSRIs inhibit the hepatic cytochrome systems responsible for metabolizing many other drugs. Of the 34 known cytochrome isoen-

zymes, SSRIs can inhibit five (1A2, 2C9, 2C19, 2D6, and 3A4). This interaction can increase the levels of many commonly used drugs, including tricyclics, benzodiazepines, antipsychotics, some anticonvulsants (phenytoin and carbamazepine), antiarrhythmics, omeprazole, cisapride, warfarin, terfenadine, astemizole, beta-blockers, and calcium channel blockers.<sup>26</sup> Conversely, other drugs that also increase serotonin availability (eg, trazodone, tricyclics, monoamine oxidase inhibitors [MAOIs], L-tryptophan) can interact with SSRIs, leading to a rapid buildup of serotonin levels and a constellation of symptoms termed the "serotonin syndrome."<sup>31</sup>

Monoamine oxidase inhibitors should be avoided as first-line treatment in primary care, because of potentially lethal interactions with vasoconstrictors, decongestants, meperidine, and other antidepressants, as





well as the risk of inducing hypertensive crises with certain foods (eg, cheese, yogurt, sour cream, beer, broad beans, and active yeast preparations).

**Need for serum level monitoring.** Patients require monitoring of serum drug levels if they are highly vulnerable to toxicity, have uncertain compliance, or take multiple drugs with potential interactions. Such patients might be prescribed antidepressants with well-established therapeutic and toxic levels, such as nortriptyline, desipramine, and imipramine.

**Risk of overdose.** For patients at significant risk of overdose, special caution should be taken when prescribing tricyclic antidepressants. Tricyclics have been reported to be the third most common cause of drug-related death (following alcohol-drug combinations and heroin).<sup>32</sup> From 70% to 80% of patients who take overdoses of tricyclics do not reach the hospital alive.<sup>33</sup> The newer agents offer an important advantage in their wider margin of safety in overdose.

**Cost.** Tricyclic antidepressants are significantly less expensive than SSRIs per pill; however, the Boston Consulting Group found that SSRIs are cheaper in the long run because they entail less physician labor and fewer hospitalizations.<sup>34</sup> In addition, SSRIs tend to be better tolerated, easier to titrate, safer to use, more likely to be taken as directed, and less likely to lead to a relapse.<sup>26</sup>

### Starting drug therapy

Before starting antidepressant drug therapy, it is important to determine if the patient has bipolar disorder, because virtually every available antidepressant agent can cause mania in patients with bipolar disorder.<sup>35,36</sup> Antidepressant drugs are not contraindicated in such patients, but they should be used cautiously: at the lowest effective dose, for the shortest time necessary,<sup>37</sup> and in conjunction with a mood stabilizer (eg, lithium, valproic acid, or carbamazepine).

TABLE 5 lists the class, starting dose, and target dose of antidepressant drugs.<sup>38,39</sup> Older adults generally need lower doses.

**Tricyclic antidepressants.** Before starting a tricyclic antidepressant, check the baseline heart rate, blood pressure (seated and

**TABLE 5**

## Drugs used for depression

DRUG	STARTING DOSE (MG/DAY)	USUAL DOSE (MG/DAY)
<b>Tricyclic antidepressants</b>		
<b>Tertiary amines</b>		
Amitriptyline (Elavil)	25–50	100–300
Clomipramine (Anafranil)	25	100–250
Doxepin (Sinequan, Adapin)	25–50	100–300
Imipramine (Tofranil)	25–50	100–300
Trimipramine (Surmontil)	25–50	100–300
<b>Secondary amines</b>		
Desipramine (Norpramin)	25–50	100–300
Nortriptyline (Aventyl, Pamelor)	25	50–200
Protriptyline (Vivactil)	10	15–60
<b>Other tricyclic antidepressants</b>		
Amoxapine (Asendin)	50	100–400
Bupropion (Wellbutrin)	200	300–450
Maprotiline (Ludiomil)	50	100–225
Mirtazapine (Remeron)	15	15–45
Nefazodone (Serzone)	100	200–600
Trazodone (Desyrel)	50	150–500
Venlafaxine (Effexor)	37.5	75–375
<b>Selective serotonin reuptake inhibitors</b>		
Fluoxetine (Prozac)	5–20	20–80
Fluvoxamine (Luvox)	50	50–300
Paroxetine (Paxil)	10–20	20–50
Sertraline (Zoloft)	50–100	50–200
<b>Monoamine oxidase inhibitors</b>		
Phenelzine (Nardil)	15	15–90
Selegiline (Eldepryl)	5	10
Tranylcypromine (Parnate)	10	10–40
<b>Adjuvants</b>		
Carbamazepine (Tegretol)	200–400	400–1200
Lithium (Eskalith, Lithobid, others)	300	600–900
Levothyroxine (Synthroid)	25 µG	25–50 µG
Valproic acid (Depakene, Depakote)	250–500	500–1500
Verapamil (Calan, Dilacor)	80	120–240
<b>Stimulants</b>		
Methylphenidate (Ritalin)	2.5–5	10–40
Pemoline (Cylert)	18.75	18.75–75
Dextroamphetamine (Dexedrine)	2.5	10–40



TABLE 6

### Instructions for patients taking antidepressants

Take the medication every day  
 Expect noticeable improvement from the medication in 2–4 weeks  
 Continue taking the medication even if you feel better  
 Do not stop taking the medication without notifying your physician  
 Contact your physician with any question

**Symptoms  
 may take up  
 to 12 weeks  
 to resolve**

standing), and renal and hepatic function. In addition, an electrocardiogram should be ordered in patients older than 40 years or with significant risk of coronary artery disease. Tricyclics must be monitored carefully and used cautiously or not at all in patients with baseline conduction abnormalities (eg, a PR interval > 200 msec, corrected QT interval > 440 msec), significant orthostatic hypotension (ie, a fall in systolic blood pressure of > 15 mm Hg when standing), tachycardia (heart rate > 100), or a ventricular or atrial arrhythmia.<sup>28,40,41</sup>

In patients with low-grade conduction disease (first-degree block, uncomplicated right or left bundle-branch block, or hemiblock), the tricyclic antidepressants must be used with caution because a higher degree of heart block could develop. In patients with more advanced conduction disease (bifascicular or trifascicular block, second- or third-degree block), tricyclic antidepressants are relatively contraindicated without a pacemaker.<sup>29</sup>

When using tricyclics, the initial dose should be gradually raised as tolerated, starting with a low daily dose given at bedtime, until a therapeutic dose is reached. The rate of increase will vary from person to person, but can be done at 3- to 4-day intervals.

#### Follow-up is vital

Regardless of what treatment the patient and physician select, frequent follow-up is vital during the initial stages of therapy. Visits should be scheduled weekly or biweekly to monitor the patient's tolerance to medication and clinical course until symptom relief becomes evident. If this type of follow-up is not possible, regular telephone contact should

be arranged.

For all available antidepressant agents, the reported rates of initial response are as high as 60% to 70% vs approximately 20% for placebo.<sup>25</sup> Patients may show some improvement by the end of the first week,<sup>42</sup> but may not fully respond before 4 to 6 weeks, or up to 12 weeks in geriatric patients.<sup>43,44</sup> Therefore, adequacy of response cannot be judged until this time.

Nonadherence is a major obstacle to effective treatment. A recent study at a large health maintenance organization<sup>45</sup> found that 30% to 40% of patients who are started on antidepressants drop out of treatment within the first 30 days. Katon et al<sup>18</sup> found that up to 60% of primary care patients stopped taking their prescribed antidepressants before completing the recommended 6 months of therapy. These investigators showed that a brief discussion about the nature and course of depression (TABLE 6) is likely to improve compliance.

#### CONTINUE TREATMENT TO AVOID RELAPSE

After an antidepressant produces a satisfactory response, it should be continued in a full therapeutic dose for at least 6 months after remission from a first episode and 12 months for a second episode.<sup>46,47</sup>

#### MAINTENANCE TREATMENT

Depression is a recurrent disorder. Patients may be prone to recurrences and should be considered for continuous prophylactic treatment if they have any of the following:

- Persistent dysthymic symptoms after recovery from a depressive episode.
- An additional nonaffective psychiatric diagnosis.
- A chronic medical condition.
- Multiple episodes of depression<sup>48</sup> (three or more episodes, or two or more severe episodes, or two episodes plus a family history of unipolar or bipolar disorder).<sup>22,49</sup>
  - A first episode before age 20.
  - A recurrent episode within 1 year after effective therapy is discontinued.<sup>22,49</sup>

The options for maintenance treatment include the various antidepressants and lithi-





um.<sup>50,51</sup> Antidepressants should be continued at full therapeutic doses. The timing and method of discontinuing maintenance therapy have not been systematically studied, but tapering, rather than abrupt discontinuation, is generally recommended because of the risk of cholinergic rebound with some medications.<sup>52</sup> Another reason for tapering rather than abrupt discontinuation is that if symptoms are going to reemerge, they will be less severe and more easily treated.

Maintenance psychotherapy should be considered for patients with unresolved intrapsychic or interpersonal conflicts that are distressing and that are thought to predispose the patient to recurrent episodes.<sup>38</sup>

## ■ MANAGING RESISTANT DEPRESSION

Initial treatment fails to achieve a response in approximately 20% to 30% of patients. In some cases the apparent lack of response is actually a result of faulty diagnosis, inadequate treatment, or failure to appreciate and remedy coexisting general medical or psychiatric conditions.<sup>53</sup> Adequate treatment for at least 6 to 12 weeks is required before concluding that the patient is not responsive.<sup>22</sup> In resistant depression, the following strategies are recommended:

- Review the diagnosis for appropriateness and coexisting medical and psychiatric conditions.
- Add an adjunctive agent to an antidepressant (TABLE 5).
- Use multiple antidepressants simultaneously.
- Consider electroconvulsive therapy.
- Consider anticonvulsants: carbamazepine and valproic acid have demonstrated some benefit.<sup>54,55</sup>

## ■ SECOND OPINIONS AND REFERRALS

Depression is eminently treatable in primary care. Physicians should aim for optimal regulation and complete remission, not partial improvement, since incomplete treatment makes subsequent treatment more difficult. Therefore, practitioners should not delay seeking a consultation when needed (TABLE 7).<sup>22</sup>

TABLE 7

### Indications for referral

Diagnostic consultation  
Need for hospitalization  
Need for intense psychotherapy  
Need for light therapy  
Need for electroconvulsive therapy  
Partial response or medication-resistant depression  
Patient request  
Poor adherence  
Severe, recurrent, or psychotic depression  
Substance abuse or dependence  
Suicidal patients  
Symptom breakthrough after a positive acute-phase response

## ■ REFERENCES

1. Unutzer J, Katon WJ, Schulberg HC, Higgs R, Marks I. Depression in a primary care setting. *Hospital Physician* 1995 (June):27-46.
2. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 study. *JAMA* 1995; 274:1511-1517.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
4. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and lost from work in a prospective epidemiologic survey. *JAMA* 1990; 264:2524-2528.
5. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the Medical Outcomes Study. *JAMA* 1989; 262:914-919.
6. US Department of Health and Human Services. Depression in primary care. Vol 1. Detection and diagnosis. In: Clinical practice guideline no. 5. Rockville, Md: Dept of Health and Human Services, 1993; AHCPR Publication No. 93-0550.
7. Nesse RE, Finlayson RE. Management of depression in patients with coexisting medical illness. *American Family Physician* 1996; 53(6):2125-2133.
8. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. *J Clin Psychiatry* 1993; 54:405-418.
9. Schwenk TL. Depression: overcoming barriers to diagnosis. *Consultant*, November 1994; 34:1553-1559.
10. Kirmayer LJ, Robins JM, editors. Current concepts of somatization: research and clinical perspectives. Washington, DC: American Psychiatric Press, 1991.
11. Kroenke K, Mangelsdorff D. Common symptoms in ambulatory care: incidence, evaluation, therapy, and outcome. *Am J Med* 1989; 86:262-266.

Obtain an ECG when starting a tricyclic in a patient older than 40





12. **Goldberg D, Hillier V.** A scaled version of the General Health Questionnaire. *Psychol Med* 1979; 9:139-145.
13. **Zung W.** A self-rating depression scale. *Arch Gen Psychiatry*, 1965; 12:63-70.
14. **Radloff L.** The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Meas* 1977; 1:385-401.
15. **Beck A, Beck R.** Screening depressed patients in family practice: a rapid technique. *Postgrad Med* 1972; 58:81-85.
16. **Brodsky H.** Think of depression-atypical presentations in the elderly. *Aust Fam Physician*, 1993; 22:1195-1203.
17. **Reynolds CF 3rd.** Depression: making the diagnosis and using SSRIs in the older patient. *Geriatrics* 1996; 5(10):28-34.
18. **Katon W, Von Korff M, Lin E, et al.** Adequacy and duration of antidepressant treatment in primary care. *Med Care* 1992; 30:67-76.
19. **Richelson E.** Treatment of acute depression. *Psychiatr Clin North Am* 1993; 16(3):461-478.
20. **Zisook S, Schuchter SR.** Depression through the first year after the death of a spouse. *Am J Psychiatr* 1991; 148:1346-1352.
21. **Zisook S, Schuchter SR, Sledge PA, Paulus M, Judd LL.** The spectrum of depressive phenomena after spousal bereavement. *J Clin Psychiatry* 1994; 55(Suppl):29-36.
22. **US Department of Health and Human Services.** Depression in primary care. Vol 2. Treatment of Major depression. In: Clinical practice guideline. No. 5. Rockville, Md: Dept of Health and Human Services, 1993; AHCPR Publication No. 93-0551.
23. **Sturm R, Wells KB.** How can care for depression become more cost-effective? *JAMA* 1995; 273:51-58.
24. **Baughman OL.** Rapid diagnosis and treatment of anxiety and depression in primary care: the somatizing patient. *J Fam Pract* 1994; 39:373-379.
25. **Beck P.** Acute therapy of depression. *J Clin Psychiatry*, 1993; 54(suppl 8):18-27.
26. **Muzina DJ, Malone DA Jr.** New antidepressants: more options for tailoring treatment. *Cleve Clin J Med* 1996; 63:406-412.
27. **Ereshefsky L, Overman GP, Karp J.** Current psychotropic dosing and monitoring guidelines. *Primary Psychiatry*, 1995; 2(5):45.
28. **Veith RC, Raskind MA, Caldwell JH, Barnes RF, Gumbrecht G, Ritchie JL.** Cardiovascular effects of tricyclic antidepressants in depressed patients with chronic heart disease. *N Engl J Med* 1982; 306:954-959.
29. **Roose SP, Glassman AH, Giardina EGV, Walsh BT, Woodring S, Bigger JT Jr.** Tricyclic antidepressants in depressed patients with cardiac conduction disease. *Arch Gen Psychiatry* 1987; 44:273-275.
30. **Skowron DM, Stimmel GL.** Antidepressants and the risk of seizures. *Pharmacotherapy* 1992; 12:18-22.
31. **Bodner RA, Lynch T, Lewis L, Kahn D.** Serotonin syndrome. *Neurology* 1995; 45:219-223.
32. **Beaumont G.** The toxicity of antidepressants. *Br J Psychiatry*, 1989; 154:454-458.
33. **Callahan M.** Epidemiology of fatal tricyclic antidepressant ingestion: implications for management. *Ann Emerg Med* 1985; 14:1-9.
34. **Boston Consulting Group.** The changing environment for U.S. pharmaceuticals. The role of pharmaceutical companies in a systems approach to healthcare. The Boston Consulting Group, Inc, 1993.
35. **Wehr TA, Goodwin FK.** Do antidepressants cause mania? *Psychopharmacol Bull* 1987; 23:61-65.
36. **Peet M.** Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants. *Br J Psychiatry* 1994; 164:549-550.
37. **Hirschfeld RMA, Clayton PJ, Cohen I, et al.** Practice guideline for treatment of patients with bipolar disorder. Work Group on Bipolar Disorder. American Psychiatric Association, 1996.
38. **Karasu TB, Docherty JP, Gelenberg A, Kupfer DJ, Merriam AE, Shadoan R.** Practice guideline for major depressive disorder in adults. Work Group on Major Depressive Disorder. American Psychiatric Association, 1996.
39. **Drug topics red book.** Montvale, NJ: Medical Economics Company, 1997.
40. **Chutka DS.** Cardiovascular effects of the antidepressants: recognition and control. *Geriatrics* 1990; 45(1):55-67.
41. **Jackson WK, Roose SP, Glassman AH.** Cardiovascular toxicity and tricyclic antidepressants. *Biomed Pharmacother* 1987; 41:377-382.
42. **Katz MM, Koslow SH, Maas JW, et al.** The timing, specificity and clinical prediction of tricyclic drug effects in depression. *Psychol Med* 1987; 17:297-309.
43. **Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W.** Use of pattern analysis to identify true drug response. A replication. *Arch Gen Psychiatry*, 1987; 44:259-264.
44. **Quitkin FM, Rabkin JG, Ross D, McGrath PJ.** Duration of antidepressant drug treatment: what is an adequate trial? *Arch Gen Psychiatry*, 1984; 41:238-245.
45. **Simon GE, Von Korff M, Wagner EH, Barlow W.** Patterns of antidepressant use in community practice. *Gen Hosp Psychiatry* 1993; 15:399-408.
46. **Schneider LS.** Pharmacologic considerations in the treatment of late-life depression. *American Journal of Geriatric Psychiatry* 1996; 4(Suppl 1):S51-S65.
47. **Prien KF, Kupfer DJ.** Continuation drug therapy for major depressive episodes: how long should it be maintained? *Am J Psychiatry* 1986; 143:18-23.
48. **Consensus Development Panel.** NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. *Am J Psychiatry* 1985; 142:469-476.
49. **Andrews JM, Nemeroff CB.** Contemporary management of depression. *Am J Med* 1994; 97(suppl 6A):24S-32S.
50. **Prien RF, Kupfer DJ, Mansky PA, et al.** Drug therapy in prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and lithium carbonate-imipramine combination. *Arch Gen Psychiatry* 1984; 41:1096-1104.
51. **Greenhouse JB, Stangle D, Kupfer DJ, Prien RF.** Methodologic issues in maintenance therapy clinical trials. *Arch Gen Psychiatry* 1991; 48:313-318.
52. **Dilsaver SC, Kranfol Z, Sackellares JC, Greden JF.** Antidepressant withdrawal syndromes: evidence supporting the cholinergic overdrive hypothesis. *J Clin Psychopharmacol* 1983; 3:157-164.
53. **Guscott R, Grog P.** The clinical management of refractory depression: a review for the clinician. *Am J Psychiatry* 1991; 148:695-704.
54. **Cullen M, Mitchell P, Brodaty H, et al.** Carbamazepine for treatment-resistant melancholia. *J Clin Psychiatry* 1991; 52:472-476.
55. **Hayes SG.** Long-term use of valproate in primary psychiatric disorders. *J Clin Psychiatry* 1989; 50(3 suppl):35-39.

**ADDRESS:** Kathleen Franco-Bronson, MD, Department of Psychiatry and Psychology, P57, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195